title: Preconditioning of rat hearts by adenosine A1 or A3 receptor activation.
abstract: Our study in rat hearts examined whether activation of adenosine A(1) or A(3) receptors improved functional recovery and reduced apoptosis resulting from low-flow ischemia. Prior to 30 min low-flow ischemia (0.6 ml/min; 6% of baseline flow), Langendorff rat hearts were preconditioned with two 5-min cycles of (a) ischemia (PC; n=7), (b) infusion of 250 nM adenosine A(1) receptor agonist 2-chloro-N(6)-cyclopentyladenosine (CCPA; n=6), or (c) infusion of 50 nM adenosine A(3) receptor agonist N(6)-(3-iodobenzyl)-adenosine-5'-N-methyl-uronamide (IB-MECA; n=8). Recovery of function was improved in PC (71+/-3%), CCPA (68+/-6%) and IB-MECA (68+/-4%) groups compared to control hearts (46+/-5%; P<0.05). Cumulative release of total purines during ischemia-reperfusion was approx. 50% lower in PC, CCPA and IB-MECA groups compared to controls (P<0.05) and was significantly correlated to the percentage functional recovery (R(2)=0.55; P<0.05). The number of cytosolic histone-associated-DNA fragments, a hallmark of apoptosis and measured by Enzyme Linked ImmunoSorbent Assay (ELISA), was small and not different between groups after 30 min reperfusion. However, CCPA (0.6+/-0.1 absorbance units) and MECA (0.7+/-0.1 units; P<0.05 vs. PC) decreased apoptosis after 150 min reperfusion compared to PC (1.4+/-0.3 units) and control (1.2+/-0.1 units) hearts. This study shows that adenosine triggers protection of function in preconditioned rat hearts via both the adenosine A(1) and A(3) receptor. In clinical practice, pharmacological stimulation of adenosine A(3) receptors may be advantageous over adenosine A(1) receptor activation due to a lack of contractile side-effects. In contrast to ischemic preconditioning, pharmacological stimulation of adenosine A(1) or A(3) receptors reduced apoptosis. Furthermore, total purine release may serve as a marker of the degree of functional protection.
authors.affiliation: Cardiochemical Laboratory, Thoraxcenter, COEUR, Erasmus University Rotterdam, 3000 DR, Rotterdam, Netherlands. dejonge@akc.azr.nl
authors.forename: Robert
authors.initials: R
authors.lastname: De Jonge
authors.forename: Mattijs
authors.initials: M
authors.lastname: Out
authors.forename: Walter J
authors.initials: WJ
authors.lastname: Maas
authors.forename: Jan W
authors.initials: JW
authors.lastname: De Jong
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects / Q000502:physiology; D003326:Coronary Circulation / Q000187:drug effects / Q000502:physiology; D006321:Heart / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology; D066298:In Vitro Techniques; D019157:Ischemic Preconditioning, Myocardial / Q000379:methods*; D008297:Male; D009200:Myocardial Contraction / Q000187:drug effects / Q000502:physiology; D058906:Purinergic P1 Receptor Agonists; D051381:Rats; D017208:Rats, Wistar; D043684:Receptor, Adenosine A3; D018047:Receptors, Purinergic P1 / Q000378:metabolism* / Q000502:physiology
chemical_list: D058906:Purinergic P1 Receptor Agonists; D043684:Receptor, Adenosine A3; D018047:Receptors, Purinergic P1